Multipotent mesenchymal stromal cells (MSC) have become important tools in regenerative and transplantation medicine. Rapidly increasing numbers of patients are receiving in vitro-expanded MSC. Culture conditions typically include FSC because human serum does not fully support growth of human MSC in vitro (MSC(FCS)). Concerns regarding BSE, other infectious complications and host immune reactions have fueled investigation of alternative culture supplements. As PDGF has long been identified as a growth factor for MSC, we tested media supplementation with platelet lysate for support of MSC proliferation. We found that primary cultures of BM-derived MSC can be established with animal serum-free media containing fresh frozen plasma and platelets (MSC(FFPP)). Moreover, MSC(FFPP) showed vigorous proliferation that was superior to classical culture conditions containing FCS. MSC(FFPP) morphology was equivalent to MSC(FCS), and MSC(FFPP) expressed CD73, CD90, CD105, CD106, CD146 and HLA-ABC while being negative for CD34, CD45 and surface HLA-DR, as expected. In addition to being phenotypically identical, MSC(FFPP) could efficiently differentiate into adipocytes and osteoblasts. In terms of immune regulatory properties, MSC(FFPP) were indistinguishable from MSC(FCS). Proliferation of PBMC induced by IL-2 in combination with OKT-3 or by PHA was inhibited in the presence of MSC(FFPP). Taken together, FCS can be replaced safely by FFPP in cultures of MSC for clinical purposes.

Characterization of human MSC propagated in animal serum-free cultures and clinical application of MSC in paediatric patients / Holzwarth, C; Kordowich, S; Isensee, G; Viebahn, S; Gieseke, F; Lang, P; Greil, J; Dominici, Massimo; Conte, Pierfranco; Handgretinger, R; Mueller, I.. - In: CYTOTHERAPY. - ISSN 1465-3249. - STAMPA. - 8:(2006), pp. 223-223. (Intervento presentato al convegno 12th Annual ISCT Meeting tenutosi a Berlin (Germany) nel 4-7 May 2006).

Characterization of human MSC propagated in animal serum-free cultures and clinical application of MSC in paediatric patients.

DOMINICI, Massimo;CONTE, Pierfranco;
2006

Abstract

Multipotent mesenchymal stromal cells (MSC) have become important tools in regenerative and transplantation medicine. Rapidly increasing numbers of patients are receiving in vitro-expanded MSC. Culture conditions typically include FSC because human serum does not fully support growth of human MSC in vitro (MSC(FCS)). Concerns regarding BSE, other infectious complications and host immune reactions have fueled investigation of alternative culture supplements. As PDGF has long been identified as a growth factor for MSC, we tested media supplementation with platelet lysate for support of MSC proliferation. We found that primary cultures of BM-derived MSC can be established with animal serum-free media containing fresh frozen plasma and platelets (MSC(FFPP)). Moreover, MSC(FFPP) showed vigorous proliferation that was superior to classical culture conditions containing FCS. MSC(FFPP) morphology was equivalent to MSC(FCS), and MSC(FFPP) expressed CD73, CD90, CD105, CD106, CD146 and HLA-ABC while being negative for CD34, CD45 and surface HLA-DR, as expected. In addition to being phenotypically identical, MSC(FFPP) could efficiently differentiate into adipocytes and osteoblasts. In terms of immune regulatory properties, MSC(FFPP) were indistinguishable from MSC(FCS). Proliferation of PBMC induced by IL-2 in combination with OKT-3 or by PHA was inhibited in the presence of MSC(FFPP). Taken together, FCS can be replaced safely by FFPP in cultures of MSC for clinical purposes.
2006
8
223
223
Holzwarth, C; Kordowich, S; Isensee, G; Viebahn, S; Gieseke, F; Lang, P; Greil, J; Dominici, Massimo; Conte, Pierfranco; Handgretinger, R; Mueller, I.
Characterization of human MSC propagated in animal serum-free cultures and clinical application of MSC in paediatric patients / Holzwarth, C; Kordowich, S; Isensee, G; Viebahn, S; Gieseke, F; Lang, P; Greil, J; Dominici, Massimo; Conte, Pierfranco; Handgretinger, R; Mueller, I.. - In: CYTOTHERAPY. - ISSN 1465-3249. - STAMPA. - 8:(2006), pp. 223-223. (Intervento presentato al convegno 12th Annual ISCT Meeting tenutosi a Berlin (Germany) nel 4-7 May 2006).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/2554
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact